Chordia Therapeutics Inc. (TYO:190A)

Japan flag Japan · Delayed Price · Currency is JPY
79.00
+1.00 (1.28%)
Aug 6, 2026, 12:30 PM JST
Market Cap6.03B -50.9%
Revenue (ttm)n/a
Net Income-1.43B
EPS-20.02
Shares Out 77.26M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume43,900
Open78.00
Previous Close78.00
Day's Range78.00 - 79.00
52-Week Range66.00 - 192.00
Beta3.14
Analystsn/a
Price Targetn/a
Earnings DateJul 15, 2026

About Chordia Therapeutics

Chordia Therapeutics Inc., a biotech company, engages in research and development of anti-cancer drugs that targets RNA deregulation stress in Japan. It develops CLK CTX-712, a CLK inhibitor, which is Phase 1 clinical trial for the treatment of relapsed or refractory malignant cancers.; CTX-177, a small-molecule inhibitor of MALT1; CDK12 inhibitor CTX-439; and GCN2 inhibitor CRD-1968099. Chordia Therapeutics Inc. was incorporated in 2017 and is based in Fujisawa, Japan. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2017
Country Japan
Stock Exchange Tokyo Stock Exchange
Ticker Symbol 190A
Full Company Profile

Financial Performance

Financial Statements